The Access to Oncology Medicines (ATOM) Coalition

The Access to Oncology Medicines (ATOM) Coalition is a new global initiative established by UICC and its partners to improve access to essential cancer medicines in LLMICs, 

Health worker handing out medicine to patient
ATOM Access to Oncology Medicines – brandmark

    In 2020, more than 3.5 million new cancer cases were diagnosed in low-and lower middle-income countries (LLMICs)[1] and an estimated 2.3 million premature deaths were caused by cancer. If left unchecked, deaths from cancer in LLMICs are expected to rise to 4 million by 2040.[2]

    Many LLMICs do not have sufficient resources to respond to the needs of people living with cancer and have a limited availability of essential medicines, diagnostics and complementary treatments required for good cancer treatment and care.[3]

    Increasing access to cancer medicines in LLMICs is challenging. Simply making cancer medicines available does not guarantee that patients will receive the right medicines at the right time. To be truly effective in addressing the problem of access, a new partnership approach is needed.

    Increasing access to essential cancer medicines

    Women in the Instanbul Oncology Institute getting cancer treatment

    The Access to Oncology Medicines (ATOM) Coalition is a new global initiative established by UICC and its partners to improve access to essential cancer medicines in LLMICs, as well as to increase the capacity for diagnosing cancer and for the proper handling and supply monitoring of these medicines.

    Priority will be given to medicines currently on the WHO Essential Medicines List (EML), or those likely to be included in the future, which treat cancers with the highest incidence-to-mortality in LLMICs (lung, colorectal, breast, cervical, prostate and childhood cancers). 

    The Coalition brings together numerous partners from civil society organisations as well as the public and private sectors with expertise in implementing cancer-focused access programmes (see full list of partners below).

    The ATOM operating model

    The ATOM ambition

    “To reduce suffering and deaths caused by cancer in low- and lower-middle income countries through improved access to and use of essential cancer medicines.”

    The ATOM Coalition has two main ambitions:

    1. increase the availability and affordability of cancer medicines
    2. increase the capacity to use these medicines appropriately.  

    This implies: 

    • working with governments and other stakeholders in selected ATOM countries to assess their needs and offer targeted training and capacity building support (eg in diagnosing cancer, the proper handling and supply monitoring of cancer medicines);
    • support generic, biosimilar and originator manufacturers to develop, register and supply quality-assured essential cancer medicines at affordable prices in selected ATOM countries;
    • facilitating the successful use of voluntary licenses [4] for patented EML medicines and new medicines that are of significant public health importance in ATOM target countries.


    In the video above, UICC President, Professor Anil D’Cruz introduces the ATOM Coalition at its launch in Geneva, Switzerland on 22 May 2022

    Driving results through partnerships

    The ATOM Coalition will work with a range of global and country-level partners currently implementing access projects in LLMICs to complement, enhance and amplify their impact. 

    It will build on the network, health expertise and experience of all partners. An important added value of ATOM is to address the current lack of connectivity between different health initiatives. ATOM seeks to complement existing access programmes and support their growth by developing synergies and addressing common challenges. 

    Further announcements will be made as new partners join the ATOM Coalition.


    The ATOM Coalition launched on 22 May 2022 will be structured as an informal alliance comprising all partners and key representatives from ATOM target countries and led by a governing council. The Union for International Cancer Control (UICC) serves as Secretariat of the Coalition and coordinates all ATOM activities implemented by Coalition partners at the global and local levels. 

    Download (
    683.93 KB
    ATOM Coalition
    Download (
    3.7 MB
    ATOM Coalition
    Download (
    2.22 MB
    Download (
    234.26 KB
    Union for International Cancer Control (UICC)
    Download (
    354.43 KB

    Current list of partners 

    *The Access to Medicine Foundation and Medicines Patent Pool (MPP) will be observers in the governance structure and collaborate with the ATOM Coalition to support its ambition to increase the availability of cancer medicines in LLMICs.

    ATOM Coalition partner logos

    [1] The World Bank defines low-income economies as those with a GNI per capita, calculated using the World Bank Atlas method, of $1,045 or less in 2020; lower middle-income economies are those with a GNI per capita between $1,046 and $4,095.

    [2] Globocan 2020: For Low-Income Countries:; for Low Middle Income Countries:

    [3] National Library of Medicine (NIH), Essential medicines for cancer: WHO recommendations and national priorities

    [4] Voluntary License. A voluntary license is an authorization given by the patent holder to a generic company, allowing it to produce a patented medicine, as if it were a generic. The license usually sets quality requirements and defines the markets in which the licensee can sell the product. The decision to grant a voluntary license, and the terms therein, can be tailored to account for many factors, including the nature of the epidemic/disease, social factors, economic considerations and the capacity of the licensee to meet and maintain quality standards for the product.

    ATOM Coalition news and updates

    Podcast "Let's talk cancer": Inequities in access to essential medicines and global shortages

    Pharmacist taking box of pills

    Opportunities, gaps and the role of the ATOM Coalition in improving access to cancer medicines in LLMICs

    Consultation at Aga Khan Hospital

    Dr Julie Gralow on improving access to cancer medicines

    Dr Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology (ASCO), a partner in the ATOM Coalition.
    View more news
    Anil D'Cruz, now UICC's Immediate-Past-President launching the ATOM Coalition in May 2022

    UICC has created several new organisations and initiatives to address long-term public health challenges and unmet needs.

    Canadian Partnership Against Cancer - building

    City Cancer Challenge (C/Can) was launched by the Union for International Cancer Control (UICC) at the 2017 World Economic Forum Annual Meeting in Davos.

    Audience listening to a conference

    The International Cancer Control Partnership (ICCP), formed in November 2012, is a group of organisations engaged in supporting country cancer control planning efforts. 

    people gathering at 2014 World Cancer Congress – Melbourne, Australia

    The McCabe Centre for Law & Cancer is the only centre of its kind in the world advancing law to prevent cancer and to protect people affected by it.

    People speaking at a NCD Alliance stand

    The Non-communicable Disease (NCD) Alliance is a civil society network uniting 2,000 federation associations, civil society organisations, scientific and professional associations, academic and research institutions to improve NCD prevention and control worldwide.

    Last update

    Thursday 25 May 2023

    Share this page